Juliane Lungershausen
- Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trialBy Martine Hoogendoorn, Maiwenn J. Al, Kai-Michael Beeh, David Bowles, J. Matthias Graf von der Schulenburg, Juliane Lungershausen, Brigitta U. Monz, Hendrik Schmidt, Claus Vogelmeier and Maureen P.M.H. Rutten-van MölkenMartine Hoogendoorn*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The NetherlandsMaiwenn J. Al*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The NetherlandsKai-Michael Beeh#INSAF Respiratory Research Institute, WiesbadenDavid Bowles¶Fakultät für Gesundheitswissenschaften, Gesundheitsökonomie und Gesundheitsmanagement, Universität Bielefeld, BielefeldJ. Matthias Graf von der Schulenburg+Institut für Versicherungsbetriebslehre, Leibniz Universität Hannover, HanoverJuliane Lungershausen§Boehringer Ingelheim International GmbH, IngelheimBrigitta U. Monz§Boehringer Ingelheim International GmbH, IngelheimHendrik Schmidt§Boehringer Ingelheim International GmbH, IngelheimClaus VogelmeierfDivision of Pulmonary Diseases, University Hospital Giessen en Marburg, Marburg, GermanyMaureen P.M.H. Rutten-van Mölken*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands
- Cost-effectiveness of tiotropium versus salmeterol: A trial-based analysis followed by a model-based extrapolationBy Martine Hoogendoorn, Maiwenn Al, J.-Matthias Graf von der Schulenburg, David Bowles, Brigitta Monz, Hendrik Schmidt, Juliane Lungershausen and Maureen Rutten-van MolkenMartine Hoogendoorn1Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, NetherlandsMaiwenn Al1Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, NetherlandsJ.-Matthias Graf von der Schulenburg2School of Economics and Management, Leibniz University Hanover, Hanover, GermanyDavid Bowles3Faculty of Health Sciences, University of Bielefeld, Bielefeld, GermanyBrigitta Monz4Boehringer Ingelheim, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyHendrik Schmidt4Boehringer Ingelheim, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyJuliane Lungershausen4Boehringer Ingelheim, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyMaureen Rutten-van Molken1Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, Netherlands
- Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trialBy Martine Hoogendoorn, Maiwenn J. Al, Kai-Michael Beeh, David Bowles, J. Matthias Graf von der Schulenburg, Juliane Lungershausen, Brigitta U. Monz, Hendrik Schmidt, Claus Vogelmeier and Maureen P.M.H. Rutten-van MölkenArticle | Published in 2012 in European Respiratory JournalMartine HoogendoornMaiwenn J. AlKai-Michael BeehDavid BowlesJ. Matthias Graf von der SchulenburgJuliane LungershausenBrigitta U. MonzHendrik SchmidtClaus VogelmeierMaureen P.M.H. Rutten-van Mölken
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.